Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们


Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements

20/08/2019Prominent biotech investor leads investment in RaceDownload
16/08/2019Trading HaltDownload
13/08/2019Race announces additional US Patent for BisantreneDownload
07/08/2019Appendix 3Y-Dr William GarnerDownload
30/07/2019Appendix 4C - quarterlyDownload
25/07/2019First patient treated in Bisantrene trial in IsraelDownload
12/07/2019Appendix 3BDownload
12/07/2019Cleansing NoticeDownload
12/07/2019Appendix 3Y-Dr William GarnerDownload
12/07/2019Change in substantial holdingDownload
1  2  3  4  5  



Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2019 Race Oncology. Website By Multiplier